Candriam S.C.A. Reduces Stock Position in United Therapeutics Corporation $UTHR

by · The Markets Daily

Candriam S.C.A. trimmed its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 50.4% in the first quarter, Holdings Channel.com reports. The fund owned 63,066 shares of the biotechnology company’s stock after selling 64,149 shares during the period. Candriam S.C.A.’s holdings in United Therapeutics were worth $37,397,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter valued at approximately $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.0%

NASDAQ UTHR opened at $547.06 on Friday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The business has a fifty day moving average of $556.70 and a 200-day moving average of $529.44. The stock has a market cap of $23.22 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $6.63 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on UTHR shares. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday. HC Wainwright upped their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $644.82.

Check Out Our Latest Stock Report on UTHR

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,851,434.88. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 603,543 shares of company stock valued at $339,592,598. 8.60% of the stock is currently owned by corporate insiders.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).